Key facts
- It has raised $14.1M; the latest was Later Stage VC in Mar 2026.
- Notable investors include CAS Star, Qiming Venture Partners, Fortune Capital, CDH Investments, TusStar Incubator — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for CSR Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for CSR Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CSR Biotech
Developer and manufacturer of super-resolution imaging instruments for living cells. The company focuses on the research, development and application of super-resolution imaging instruments for living cells and provides services including customized cell sample production service, customized cell sample high-throughput detection service, customized cell sample imaging experiment service, customized image post-processing and quantitative analysis service, and customized high-dimensional spatio-temporal data visualization service, enabling bio researchers with tool to discover new disease biomarkers and innovative drug targets.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2019
- Employees
- 80
- Website
- csr-biotech.com/
- Ownership
- Privately Held (backing)
CSR Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CSR Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CSR Biotech in its N-PORT filings yet. We sweep new filings monthly.